FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
|Videos|November 20, 2019
Follicular Lymphoma: Treating Early Progressors
Follicular Lymphoma: Treating Early Progressors
Advertisement
Case: A 62-Year-Old Male with Follicular Lymphoma
H & P:
- A 62-year-old man presents with lower abdominal discomfort and rapid weight loss over last 3 months
- PMH: Hypertension managed by statin
- PE: palpable inguinal lymphadenopathy
Diagnostic Work-Up
- Hematologic results
- ANC: 1200 /µL
- Platelets: 89,000 /µL
- β2-microglobulin: 3.5 mg/L
- Serum LDH: 230 IU/L
- Imaging: PET/CT reveals axillary and bilateral inguinal lymphadenopathy; 5 masses (~3cm each)
- Biopsy: FL, grade 2
- FLIPI status: High-risk
- Ann Arbor: Stage IV
- ECOG PS: 1
Treatment
- Patient treated with obinutuzumab + bendamustine
- Completed 6 cycles, achieved CR
Advertisement
Related to this article
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
5